Australia's most trusted
source of pharma news
Sunday, 08 September 2024
Posted 25 July 2024 PM
A range of "mid-size to multibillion-dollar companies" are now evaluating the potential of Noxopharm's Sofra platform following the signing of several Material Transfer Agreements (MTAs), the Australian biotech has revealed.
The companies are testing a number of novel and proprietary assets from the platform which contains, among others, the SOF-VAC mRNA vaccine enhancer and SOF-SKN lupus medication.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.